DE69904302D1 - Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung - Google Patents

Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung

Info

Publication number
DE69904302D1
DE69904302D1 DE69904302T DE69904302T DE69904302D1 DE 69904302 D1 DE69904302 D1 DE 69904302D1 DE 69904302 T DE69904302 T DE 69904302T DE 69904302 T DE69904302 T DE 69904302T DE 69904302 D1 DE69904302 D1 DE 69904302D1
Authority
DE
Germany
Prior art keywords
formula
farnesyl transferase
piperid
production
transferase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69904302T
Other languages
English (en)
Other versions
DE69904302T2 (de
Inventor
Seung Shin
Sung Koh
Il Lee
Ho Lee
Hyun Kim
Ho Chung
Hwa Kim
Hwan Kwak
Gu Ro
Ae Ahn
Saeng Choi
Hoon Oh
Mi Kim
Hwa Lee
Sung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980002777A external-priority patent/KR100388789B1/ko
Priority claimed from KR1019980028340A external-priority patent/KR100388792B1/ko
Priority claimed from KR10-1998-0032150A external-priority patent/KR100388794B1/ko
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Application granted granted Critical
Publication of DE69904302D1 publication Critical patent/DE69904302D1/de
Publication of DE69904302T2 publication Critical patent/DE69904302T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
DE69904302T 1998-02-02 1999-02-01 Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung Expired - Fee Related DE69904302T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1019980002777A KR100388789B1 (ko) 1998-02-02 1998-02-02 피롤구조를갖는파네실전이효소억제제및그의제조방법
KR19980002776 1998-02-02
KR1019980028340A KR100388792B1 (ko) 1998-02-02 1998-07-14 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR10-1998-0032150A KR100388794B1 (ko) 1998-08-07 1998-08-07 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
PCT/KR1999/000051 WO1999038862A1 (en) 1998-02-02 1999-02-01 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof

Publications (2)

Publication Number Publication Date
DE69904302D1 true DE69904302D1 (de) 2003-01-16
DE69904302T2 DE69904302T2 (de) 2003-08-14

Family

ID=27483262

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69904302T Expired - Fee Related DE69904302T2 (de) 1998-02-02 1999-02-01 Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung

Country Status (12)

Country Link
US (1) US6436960B1 (de)
EP (1) EP1058683B1 (de)
JP (1) JP3283032B2 (de)
CN (1) CN1158277C (de)
AT (1) ATE229017T1 (de)
AU (1) AU745855B2 (de)
BR (1) BR9908545A (de)
CA (1) CA2320233C (de)
DE (1) DE69904302T2 (de)
ES (1) ES2185307T3 (de)
PT (1) PT1058683E (de)
WO (1) WO1999038862A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100388792B1 (ko) * 1998-02-02 2003-09-22 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR100388794B1 (ko) * 1998-08-07 2003-10-10 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
US6511978B1 (en) * 1999-04-13 2003-01-28 Lg Life Sciences, Ltd. Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
US7035932B1 (en) * 2000-10-27 2006-04-25 Eric Morgan Dowling Federated multiprotocol communication
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
NZ540148A (en) 2002-12-20 2007-11-30 Glaxo Group Ltd Benzazepine derivatives for the treatment of neurological disorders
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
KR20060101488A (ko) * 2003-10-17 2006-09-25 인사이트 코포레이션 매트릭스 메탈로프로테이나제의 억제제로서의 치환된시클릭 히드록사메이트
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
MY162024A (en) 2006-08-28 2017-05-31 La Jolla Inst Allergy & Immunology Antagonistic human light-specific human monoclonal antibodies
EP2068923A4 (de) 2007-03-30 2010-11-24 Medimmune Llc Antikörper mit verminderten deamidierungsprofilen
EP2668210B1 (de) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit-antikörper und ihre verwendungen
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
EP3003390B1 (de) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54-antikörper und verwendungen davon
RU2699289C2 (ru) 2013-08-26 2019-09-04 Байонтек Рисерч Энд Дивелопмент, Инк. НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015271685B2 (en) 2014-06-04 2021-02-18 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
EP3383908A1 (de) 2015-12-02 2018-10-10 Stsciences, Inc. Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
EP3909983A1 (de) 2015-12-02 2021-11-17 STCube & Co. Inc. Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
AU2019306165A1 (en) 2018-07-20 2021-02-25 Pierre Fabre Medicament Receptor for vista

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
CZ229594A3 (en) * 1992-03-25 1995-04-12 Pfizer Peptides, process of their preparation, their use and pharmaceutical compositions based thereon
GB9312806D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
EP0891351A1 (de) * 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitoren von farnesylprotein-transferase
JP2000504023A (ja) * 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
AU716153B2 (en) * 1996-04-03 2000-02-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036900A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997038665A2 (en) * 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1188407C (zh) * 1997-11-28 2005-02-09 Lg化学株式会社 具有法尼基转移酶抑制活性的咪唑衍生物及其制备方法

Also Published As

Publication number Publication date
PT1058683E (pt) 2003-04-30
JP2002501918A (ja) 2002-01-22
AU2188699A (en) 1999-08-16
DE69904302T2 (de) 2003-08-14
AU745855B2 (en) 2002-04-11
EP1058683B1 (de) 2002-12-04
WO1999038862A1 (en) 1999-08-05
CA2320233C (en) 2004-07-27
ATE229017T1 (de) 2002-12-15
CA2320233A1 (en) 1999-08-05
JP3283032B2 (ja) 2002-05-20
BR9908545A (pt) 2001-10-02
ES2185307T3 (es) 2003-04-16
CN1289331A (zh) 2001-03-28
EP1058683A1 (de) 2000-12-13
CN1158277C (zh) 2004-07-21
US6436960B1 (en) 2002-08-20

Similar Documents

Publication Publication Date Title
DE69904302T2 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
HUP0400636A2 (hu) Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk
NO990551L (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9802762A2 (hu) Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE146473T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
NO20040881L (no) Orale antidiabetes midler.
NO20002099L (no) 6,11-bro-erytromycinderivater
DK1233953T3 (da) Nye benzoethiadiazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende samme
ATE141606T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
NO20052491L (no) Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme
NO20045132L (no) Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
ATE165822T1 (de) Chinolin-4-carbonylguanidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
EA200000389A3 (ru) Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции
EP1123923A4 (de) Dihydropyridin-derivate und drogen gemenge, die diese enthalten
DE3480839D1 (de) Benzimidazol-derivat, verfahren zu seiner herstellung und pharmazeutische zusammensetzung.
NO975402L (no) Nye benzopyran forbindelser, fremgangsmÕte ved fremstilling av dem og farmas÷ytiske sammensetninger som inneholder dem
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
HUP0303676A2 (hu) Helyettesített 4-fenil-1-(1-fenil-ciklohexil)-1,2,3,6-tetrahidropiridinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE3668888D1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee